Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the PSP US Deferral plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific insider transaction rather than general financial performance.
Material Changes
The only material change disclosed is an increase in American Depositary Receipts (ADRs) held by Mr. D E Troy. This increase resulted from the re-investment of the dividend paid to shareholders on April 7, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a routine disclosure of a director's transaction in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Type: Increase in ADR holdings via dividend re-investment.
- Individual Involved: Mr. D E Troy.
- Transaction Price: $41.29 per ADR.
- Quantity Acquired: 345 ADRs.
- Dividend Date: April 7, 2011.
- Filing Date: April 28, 2011.